novadiscovery is a developer of a drug discovery platform in silico clinical trials designed to de-risk, optimize research and development along with curbing the cost of discovering new drugs. The company's platform uses mathematics and intelligent algorithms to build a community of virtual patients as on-demand digital lab rats, enabling scientists and biotech, pharma companies to predict drug efficacy and create the target combination.
Little Green House have a vision to make our daycare a place where everyone is free to be who they are and to become who they want to be.
Coorpacademy S.A. is a Swiss company based in Lausanne, established in 2013. It specializes in developing online training courses and innovative learning solutions, including MOOCs. The company offers a learning experience platform that features a diverse catalog of training courses, which are designed to provide short, accessible sessions that users can engage with at any time and on various devices. This platform aims to revolutionize digital learning for employees by delivering customized content tailored to individual needs. Coorpacademy was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre.
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; and the translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington.
Coorpacademy S.A. is a Swiss company based in Lausanne, established in 2013. It specializes in developing online training courses and innovative learning solutions, including MOOCs. The company offers a learning experience platform that features a diverse catalog of training courses, which are designed to provide short, accessible sessions that users can engage with at any time and on various devices. This platform aims to revolutionize digital learning for employees by delivering customized content tailored to individual needs. Coorpacademy was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre.
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; and the translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington.
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; and the translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington.
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.
Since 2001, BPA Solutions is a leading global provider of innovative business software solutions based on Microsoft Office 365 and SharePoint technologies. BPA develops ready-to-use regulatory software solutions – Quality, Risk, GDPR – to improve organizations’ processes, products, services and simplify regulatory compliance. BPA Solution Builder gives developers a wide range of integrated components to accelerate development and maximize user experience with SharePoint. Headquartered in Switzerland, with an office in Seattle USA, BPA is ready to support your digital workplace initiatives.
At Skioo, we want every skiing experience to be as smooth as fresh powder snow. We’re obsessively passionate about it, and our mission is to help people achieve it, too. Thanks to the Skioo Pass skiers have instant access to a large network of ski partner resorts in Switzerland and around the world. Moreover, the Skioo App creates a community of snow lovers and offers additional information and other features to fully enjoy the ski experience. Our team is made up of enthusiasts of ski and outdoor activities, backed up by amazing partners. Skioo is a Skitude company since 2019 Key tech partners: Skidata AG - Team Axess AG
Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or join in with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn...
Compliant Concept AG, based in Dübendorf, Switzerland, specializes in developing advanced bed systems aimed at the treatment and prevention of pressure ulcers. Founded in 2009 as a spinoff from the Empa and ETH Zurich, the company leverages technology to enhance patient care in hospitals and nursing homes. Its intelligent bed systems incorporate mobility monitors that assess clinical risks and identify factors influencing pressure ulcer development, such as medication and pre-bedtime activities. By automating routine tasks, Compliant Concept's solutions help reduce the workload of healthcare professionals, allowing them to focus on providing better care to patients while improving overall comfort and efficiency in healthcare settings.
Spinomix is a Swiss technology platform company based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), specializing in innovative sample processing solutions for the life sciences sector. The company aims to establish a new standard for the processing of biochemical substances, enhancing the quality and efficiency of sample capture and extraction, which is crucial for accurate diagnostics in various human diseases. Spinomix's flagship products, MagPhase™ and FibroTrap™, significantly improve the analysis of complex samples such as blood, urine, and food matrices, which are often challenging to process. The company recognizes the labor-intensive nature of current sample processing methods and sees a substantial opportunity to streamline these processes. Spinomix targets key growth markets, including nucleic acids extraction, cell separation, food safety, and molecular diagnostics for infectious diseases. By focusing on product innovation and market validation, Spinomix is building collaboration agreements with industry leaders to validate its technologies and develop strategic commercial partnerships for licensing its products.
Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.
At Skioo, we want every skiing experience to be as smooth as fresh powder snow. We’re obsessively passionate about it, and our mission is to help people achieve it, too. Thanks to the Skioo Pass skiers have instant access to a large network of ski partner resorts in Switzerland and around the world. Moreover, the Skioo App creates a community of snow lovers and offers additional information and other features to fully enjoy the ski experience. Our team is made up of enthusiasts of ski and outdoor activities, backed up by amazing partners. Skioo is a Skitude company since 2019 Key tech partners: Skidata AG - Team Axess AG
Tweasy is a company that offers an online marketing platform designed to assist small businesses, clubs, and associations in enhancing their customer engagement. The Tweasy application consolidates news, promotions, surveys, and various information generated by these organizations, facilitating effective communication with their clientele. By leveraging a cloud-based and Software as a Service (SaaS) model, Tweasy enables its users to implement local, social, and mobile marketing strategies, thereby fostering strong and profitable relationships with their customers.
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; and the translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington.
Private Equity Round in 2012
Agendia, Inc. is a biotechnology company based in Irvine, California, founded in 2003. The company specializes in developing and distributing genomic-based diagnostic kits aimed at improving cancer treatment for patients. Agendia's molecular diagnostic technology offers insights into a patient's genomic profile, allowing physicians to make informed decisions regarding personalized treatment plans. The company's breast cancer tests utilize a comprehensive analysis of the human genome to evaluate individual risks for metastasis and determine the most appropriate therapies. This includes identifying which patients would benefit from chemotherapy or hormonal treatments, as well as those who may avoid more aggressive interventions in favor of less intensive and cost-effective options.
Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.
Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.
Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Based in Lexington, Massachusetts, the company is advancing several clinical-stage candidates, including CA-4948, an oral small molecule currently undergoing Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia. Other notable candidates in its pipeline include CI-8993, a monoclonal antibody targeting T cell activation, and Fimepinostat, a dual inhibitor for MYC-altered diffuse large B-cell lymphoma. Additionally, Curis is developing CA-170 for advanced solid tumors and CA-327, which is in pre-investigational stages. The company has established collaborations with leading organizations, including F. Hoffmann-La Roche and Genentech for the commercialization of Erivedge, a treatment for advanced basal cell carcinoma, and Aurigene Discovery Technologies for advancing small molecule compounds in immuno-oncology and precision oncology. Curis aims to leverage its expertise in signaling pathway drug technologies to create targeted therapies that address unmet medical needs in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.